Autologous stem cell transplantation for multiple sclerosis. Rapid scoping review
Health technology assessment
|Published
The Norwegian Institute of Public Health was commissioned by The Ordering forum for The National System for Managed Introduction of New Health Technologies within the Specialist Health Service in Norway to identify and map ongoing and published randomized controlled trials on the effect of autologous stem cell transplantation for the treatment of multiple sclerosis.
Key message
The Norwegian Institute of Public Health was commissioned by the Ordering forum for the National System for Managed Introduction of New Health Technologies within the Specialist Health Service in Norway to identify and map ongoing and published randomized controlled trials on the effect of autologous stem cell transplantation for the treatment of multiple sclerosis.
Method
We performed a systematic literature search, identifying studies published as of 2014. We screened and sorted the studies in tables, categorized by transplantation type and study name. The study authors’ conclusions were cited. We did not perform a critical appraisal of the studies’ methodological quality, nor did we analyze the results.
Result
- We identified five studies on hematopoietic stem cell transplantation (HSCT). One of the studies, MIST, is completed and published. The remaining studies are ongoing, so far with no reported results.
- We identified ten studies on mesenchymal stem cell transplantation (MSCT). Seven studies are completed, of which five have reported results. Three studies are ongoing, so far with no reported results.
We present links to study registries and references to available publications with study results.
